Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma-Reference-Cited by-同舟云学术

Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma

Published:2020-08-11 Issue:2 Volume:56 Page:368-375
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Lemieux Christopher,Muffly Lori S.^ORCID,Rezvani Andrew,Lowsky Robert,Iberri David J.,Craig Juliana K.,Frank Matthew J.,Johnston Laura J.,Liedtke Michaela,Negrin Robert,Weng Wen-Kai,Meyer Everett,Shizuru Judith^ORCID,Shiraz Parveen^ORCID,Arai Sally,Miklos David B.,Sidana Surbhi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-020-01026-7.pdf

Reference43 articles.

1. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118:4519–29. https://doi.org/10.1182/blood-2011-06-358812.

2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:2758–65. https://doi.org/10.1200/JCO.2008.20.8983.

3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97. https://doi.org/10.1056/NEJM199607113350204.

4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83. https://doi.org/10.1056/NEJMoa022340.

5. Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, et al. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014;132:211–9. https://doi.org/10.1159/000357394.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma;Cancers;2024-08-23

2. The Effect of Age on High-Dose Therapy with Autologous Stem Cell Support in Multiple Myeloma: A Single-Center Experience;Journal of Clinical Medicine;2024-07-16

3. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review;Journal of Geriatric Oncology;2024-04

4. Bendamustine, prednisone and bortezomib (BPV) induction therapy prior autologous stem cell transplantation (ASCT) in 135 newly diagnosed multiple myeloma patients: comparison between patients with normal and impaired renal function;2023-12-11

5. Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis;BMC Cancer;2023-05-16